We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Inverness Acquires Advantage Diagnostics

By Labmedica staff writers
Posted on 30 Jun 2004
In a transaction that will expand the company's intellectual property, Inverness Medical Innovations, Inc. (Waltham, MA, USA) has acquired through a merger transaction all of the stock of Advantage Diagnostics Corp. (ADC, Sunnyvale, CA, USA) for U.S.$2.4 million in cash and a pay-off of ADC debt of $210,000.

Avantage Diagnostics is a lateral flow diagnostic company that specializes in rapid test development and component manufacturing. The company was formed in 1998 by Dr. David Charlton, inventor of one of the key families of lateral flow patents central to the rapid diagnostic industry. Advantage Diagnostics recently developed for Inverness' Applied Biotch (ABI) unit a proprietary drugs-of-abuse test system that combines greatly improved test performance and accuracy with increased efficiency in production and lower manufacturing costs. The acquisition eliminates a future royalty stream related to that product line payable by ABI to ADC under a license agreement.

Inverness Medical Innovations is a global developer of diagnostic devices and is presently exploring new opportunities for its proprietary electrochemical and other technologies in a variety of professional diagnostic and consumer applications, with a focus on women's health, cardiology, and infectious disease.




Related Links:
Inverness Medical Innovations

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Drug Testing Assays
Atellica DT 250 Analyzer

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
30 Jun 2004  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
30 Jun 2004  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
30 Jun 2004  |   Industry